2 research outputs found
COPING WITH CANCER OF THE LUNG: PSYCHOLOGICAL ADAPTATION AND RESILIENCE PATHWAYS
No full textLung cancer poses not just serious physical obstacles but also considerable emotional suffering, affecting patients’ mental well-being and overall quality of life. The diagnosis frequently provokes strong emotional responses such as fear, anxiety, and sorrow, further intensified by stigma and changes to identity. Psychological adjustment the manner in which individuals emotionally and cognitively adapt to the truths of their condition is essential for effective coping. Resilience, which is the capacity to sustain or recover psychological health in the face of challenges, is crucial for promoting positive adaptation to lung cancer. This review compiles existing insights on the coping mechanisms and resilience approaches used by lung cancer patients. Adaptive coping strategies like cognitive reframing, solving problems, and obtaining social support assist in reducing distress and enhancing emotional regulation. Factors that protect, such as robust social connections, spirituality, and previous coping experiences, enhance resilience. Therapeutic approaches, particularly cognitive-behavioral therapy, mindfulness-based stress reduction, and meaning-centered psychotherapy, additionally boost patients’ ability to handle psychological difficulties and maintain hope. Healthcare professionals play a crucial role in promoting psychological adjustment and resilience through compassionate communication, regular mental health assessments, and coordinated psychosocial assistance
Peer Review History:
Received 6 June 2025; Reviewed 10 July 2025; Accepted 21 August; Available online 15 September 2025
Academic Editor: Dr. Nuray Arı, Ankara University, Turkiye, [email protected]
Reviewers:
Dr. Eyassu Mathewos, School of public health, college of health sciences and medicine, Wolaita Soddo university- P.O. Box 158, Wolaita Soddo, Ethiopia.
Dr. Fátima Morales Marín, University of Murcia, Spain, [email protected]
POPULATION AGING AND THE RISE OF REFRACTORY LEUKEMIAS: SURVEILLANCE, SCREENING AND STRATEGIC HEALTH PLANNING
No full textThe global demographic shift towards an aging population has led to a marked increase in the incidence of refractory leukemias, posing significant challenges for healthcare systems worldwide. Older adults are disproportionately affected by leukemias that are resistant to conventional therapies, resulting in poorer prognoses and increased morbidity. This review explores the multifaceted impact of population aging on the epidemiology and management of refractory leukemias, highlighting the urgent need for tailored public health interventions. Effective surveillance systems are critical to monitoring trends in leukemia incidence, treatment resistance, and outcomes among elderly populations. Enhanced data collection and integration of molecular and clinical markers can improve early identification of high-risk individuals and inform resource allocation. Additionally, risk-based screening strategies adapted to the unique needs of older adults have the potential to facilitate earlier diagnosis and improve responsiveness to treatment, ultimately reducing the progression to refractory disease. Strategic health planning that incorporates multidisciplinary care models, public health policy initiatives, and community engagement is essential to address the complex care needs of elderly leukemia patients. Investments in healthcare infrastructure, provider training, and supportive services will improve quality of life and clinical outcomes. Collaborative efforts to integrate surveillance and screening into comprehensive health plans can help mitigate the growing public health burden of refractory leukemias in aging populations.
Peer Review History:
Received 9 August 2025; Reviewed 14 September 2025; Accepted 23 October; Available online 15 November 2025
Academic Editor: Dr. Nuray Arı, Ankara University, Turkiye, [email protected]
Reviewers:
Dr. Marwa A. A. Fayed, University of Sadat City, Egypt, [email protected]
Dr. Mohammad Bayan, Faculty of Pharmacy, Philadelphia University, P.O. Box: 1 Philadelphia University 19392 Jordan, [email protected]
